---
With a clear focus on further advancing its climate protection activities based on the latest findings of climate science, schülke joined the Science Based Targets Initiative (SBTi) in June 2022 and has thus committed itself to meeting the targets of the Paris Climate Change Agreement. Now schülke has submitted its specific targets to SBTi for validation. Verification of the targets is expected by the end of this year.
The submission to SBTi was preceded by an intensive process and a comprehensive analysis of schülke's global ecological footprint for 2021: emissions in Scopes 1, 2 and 3 were recorded, evaluated and a baseline was established to track progress. Scope 1 are the direct emissions of a company, Scope 2 the indirect emissions from purchased energy and Scope 3 the indirect emissions within the value chain. On this basis, schülke has drawn up targets for the year 2030, which are now being validated by SBTi.
schülke CEO, Stefan Kukacka, comments on this milestone: "As in everything we do, we also strive for excellence when it comes to meeting climate targets. We have therefore gladly committed ourselves to the ambitious Science Based Targets initiative. The entire workforce in all regions worldwide was involved in collecting the data and developing our targets. In doing so, we have initiated a transformation in our company that is impressive and of which we are all proud."
SBTi is a collaboration between the Carbon Disclosure Project (CDP), the UN Global Compact, the World Resources Institute (WRI) and the World Wide Fund for Nature (WWF). The initiative defines best science-based practices and independently assesses corporate targets. More than 4,600 companies worldwide are already working with SBTi.
In addition to its commitment to clear climate targets, schülke is continuously reducing the use of energy and resources with the help of modern technologies, further developing its product portfolio and making it more sustainable. Consistent quality and effectiveness of the products at the highest standard to ensure the safety of patients and healthcare professionals are a matter of course.
Further information on schülke's commitment and goals in the area of sustainability can be found at: https://www.schuelke.com/de-de/ueber-uns/verantwortung/nachhaltigkeit.php
Details of schülke's emission reduction targets will be published on the SBTi website after verification by SBTi: https://sciencebasedtargets.org/
From left to right: Annett Keizer, ESG & Sustainability Manager; Florian Seja, Controlling; Dr. Nicole Steinhorst, Director Scientific Medical & Clinical Affairs / Chief Sustainability Officer; Stefan Kukacka, Managing Director / Chief Executive Officer; Ingrid Breul-Husar, Corporate Communications Manager; Matthias Kallert, Team Lead Engineering. Missing: Steffen Bahns, Sourcing Manager Procurement.
Schülke & Mayr GmbH (schülke)
Schülke & Mayr GmbH, headquartered in Norderstedt near Hamburg, has been a leading global provider in the field of infection prevention and control for almost 135 years. Infectious agents know no borders - this has always been true and is all the more important in today's globalized world. Committed to the mission "We protect lives worldwide", schülke actively contributes to the safety and health protection of people with its strategic business areas Healthcare, Over the Counter (OTC) and Life Sciences. With strong brands such as octenisept®, kodan®, desderman® and microshield®, schülke is one of the international market leaders in the field of wound and mucous membrane antiseptics as well as hand and surface disinfection in German hospitals. In more than 80 countries around the world, people rely on schülke products every day. With its wide range of high-quality and innovative products, expert advice and reliable service, schülke offers holistic concepts for infection treatment and prevention in professional healthcare, for end users and the pharmaceutical sector. schülke has more than 1,100 dedicated employees, over 20 subsidiaries and three production sites in Germany (schülke), France (Bioxal) and Brazil (Vic Pharma). In 2021 alone, schülke contributed three billion product applications to protect patients and health care professionals in hospitals from infections.
More about schülke at: www.schuelke.com